THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA — FDA record Z-0567-2022

Reported ongoing

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Dec 10, 2021. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product
THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA
Reason
This recall was initiated to recover a Dunnage Case, which is a case of three (3) CLXUSA kits. This Dunnage Case was shipped on 02-Dec-2021. Dunnage is used during the sterilization process and is not intended for customer use.
Classification
Class II
Recalling firm
Mallinckrodt Pharmaceuticals Ireland Ltd
Quantity
3
Agency-reported status
Ongoing
Source record identifier
Z-0567-2022

Open the official record

What the recall classes mean. Classification is an agency assessment, not individual medical advice.

Lot and product identifiers

Label fieldDetails supplied by the agency
Lot, code or applicabilityDunnage case consists of a random unknown lot, which may have been shipped in place of Kit lot K341

Match all identifying details in the current notice. A brand name alone is not enough.

Distribution

US Nationwide distribution in the states of CA, FL, GA, MA, MI, NC, NJ, NY, OH, TN, TX, VA, WV.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Report date
Feb 16, 2022
Recall initiation date
Dec 10, 2021
Center classification date
Feb 7, 2022

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

Related records